Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Genetically modified anti-third party central memory T cells and use of same in immunotherapy

Genetically modified anti-third party central memory T cells and use of same in immunotherapy

US Patent 11844827 · Granted Dec 19, 2023

Estimated economic value: $28,594,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Genetically modified anti-third party central memory T cells and use of same in 2025
Genetically modified anti-third party central memory T cells and use of same in 2025
Genetically modified anti-third party central memory T cells and use of same in 2025
Genetically modified anti-third party central memory T cells and use of same in 2025
Genetically modified anti-third party central memory T cells and use of same in 2025
Veto cells generated from memory T cells2025
Veto cells generated from memory T cells2025
Veto cells generated from memory T cells2025
Triple combination antibody therapies2024
Anti third party central memory t cells, methods of producing same and use of sa2024
Anti third party central memory t cells, methods of producing same and use of sa2024
Anti third party central memory t cells, methods of producing same and use of sa2024